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Abstract
Background: Care home residents, especially those lacking capacity to provide consent for themselves, are
frequently excluded from research, thus limiting generalisability of study findings. We set out to explore
stakeholders’ views about the ethical and practical challenges associated with recruiting care home residents into
research studies.
Methods: Qualitative individual interviews with care home residents (n = 14), their relatives (n = 14), and general
practitioners (GPs) (n = 10), and focus groups (n = 2) with care home staff. Interviews focused on the issues of older
adults consenting to research in care homes, including advanced consent, in general and through reference to a
particular study on the use of probiotics to prevent Antibiotic Associated Diarrhoea. Data were analysed using a
thematic approach incorporating themes that had been identified in advance, and themes derived from the data.
Researchers discussed evidence for themes, and reached consensus on the final themes.
Results: Respondents were generally accepting of low risk observational studies and slightly less accepting of low
risk randomised trials of medicinal products. Although respondents identified some practical barriers to informed
consent, consenting arrangements were considered workable. Residents and relatives varied in the amount of detail
they wanted included in information sheets and consent discussions, but were generally satisfied that an advanced
consent model was acceptable and appropriate. Opinions differed about what should happen should residents lose
capacity during a research study.
Conclusions: Research staff should be mindful of research guidance and ensure that they have obtained an
appropriate level of informed consent without overwhelming the participant with unnecessary detail. For research
involving medicinal products, research staff should also be more explicit when recruiting that consent is still valid
should an older person lose capacity during a trial provided the individual did not previously state a wish to be
withdrawn if they lose capacity, and provided they do not indicate objection or resistance after loss of capacity.
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Background
Older people are often excluded from research studies
on the basis that their inclusion would present the re-
search team with ethical or practical difficulties [1]. Such
exclusion has been described as unjustifiable and scien-
tifically flawed because it is inappropriate, and possibly
dangerous, to apply the results of research to the man-
agement of older adults in general when the research
excluded an important sub-group of older adults [2,3].
There are many ethical and practical challenges in-
volved in conducting research with older people, which
will have contributed to their under-representation in
research studies. These challenges include difficulty in
recruiting older people due to their physical and cognitive
impairments, [4-7] obtaining consent, [7-12] responding
to concerns from family members, [7,13,14] and higher
rates of attrition from the studies [7,9,11,15]. On the other
hand, fewer family and employment commitments of
older people may facilitate their participation [2]. Add-
itional challenges in conducting research within care
homes include collecting data during the care homes’ busy
schedule, along with issues of privacy (for example staff
entering a resident’s room during an research interview,
[12]) or poor staff compliance with the intervention and
data protection protocols [7].
People in care homes (4% of those aged 75–84, and
17% of those aged over 85 in the UK), [16] most of
whom have multiple physical and mental health and
social care needs, have been particularly prejudiced in
terms of opportunities to participate in research, and there
have been recommendations for more studies to be
conducted within care home settings [17]. Researchers
have been given guidance on how to achieve this. For ex-
ample, a toolkit developed by the National Institute of
Health Research has been developed to assist researchers
with best practice on preparing and conducting research
in care homes [18]. Gaining informed consent can be a
major challenge due to the high prevalence of dementia
and consequent lack of mental capacity of many residents.
The legal framework governing how consent is obtained
also differs for different types of research study. Observa-
tional studies in the UK are governed by the Mental Cap-
acity Act (2005), (section 30–34), which states that for
those people who are deemed not to have capacity, a ‘per-
sonal consultee’ (somebody close to the person, but not
acting in a paid capacity) is asked to give their advice on
whether they believe the person would want to be in-
volved [19]. Typically, the personal consultee is a rela-
tive or friend. Investigations of medicinal products are
governed by the Medicines for Human Use (Clinical
Trials) Regulations (2004), which state that legal consent
to participate in the trial for those who lack capacity
must be given by a Personal Legal Representative (fam-
ily member, close friend) and, if such a person cannot be
found, a Professional Legal Representative (doctor, so-
licitor, professional advocate), but not anyone involved
in the study [20].
An advanced consent model has been advocated for
patients who may not be able to give their consent to
participation in a clinical trial at the time of randomisa-
tion [21]. Advanced consent may be particularly useful if
the study intervention is administered in an emergency
setting [22]. Other researchers have embedded qualita-
tive sub-studies within trials to investigate participants’
perspectives of the trial recruitment processes [23-25].
To our knowledge there has been no previous research
that has explored the views of residents, their relatives,
or care home staff, about the potential, and problems, of
conducting research within care homes, including issues
of advanced consent and loss of capacity. Therefore,
while conducting an observational study to assess preva-
lence of antibiotic prescribing and antibiotic associated
diarrhoea in care homes (the Probiotics for Antibiotic
Associated Diarrhoea (PAAD) study stage 1), we also
conducted an embedded qualitative sub-study to investi-
gate the views and experiences of residents, relatives,
care home staff, and GPs about the practical and ethical
challenges of conducting research (including trials of
medicinal products) in care homes. More specifically, we
were interested in the views of these stakeholders about
advanced models of consent and what should happen if
a study participant loses capacity during a trial of a me-
dicinal product. Our aim was to generate ‘bottom up’
data from the perspectives of key people that would be
involved in study implementation, to improve the setup
and conduct of a subsequent low-risk randomised con-
trolled trial (ISRCTN 79,548,440) of a probiotic versus a
placebo given alongside antibiotics (PAAD stage 2) and
to share such guidance with others conducting research
in care homes. By ‘low-risk’ we refer to the core-set of
risks inherent in the trial protocol which impact on the
participants’ safety and rights. The risks associated with
the IMP (Investigational Medicinal Product) (in our case
a probiotic) should determine the trial procedures for
monitoring the safety of patients [26]. In respect to the
PAAD stage 2 study, by ‘advanced consent’ we refer to a
situation where residents are recruited for a 12 month
period, but only randomised to receiving a probiotic or
placebo at the next point at which they are prescribed
an antibiotic (which may be anything from the next day
to 365 days after giving consent.
Method
We used qualitative research methods because this
would allow us to explore in-depth respondents’ views
and experiences, including topics that we were unable to
predict in advance. We thought it important to under-
stand the views of a range of stakeholders and so our
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respondents included residents, relatives, care home staff,
and GPs who have a responsibility for the general medical
care of residents and who may be asked to assess eligibility
for research studies. We recruited through 11 care homes
in South Wales, which were participating in the PAAD
Stage 1 study. Data collection was undertaken through a
combination of face-to-face interviews with residents,
relatives and GPs to facilitate in-depth reflection of re-
spondents’ own involvement in research studies, and focus
groups amongst care home staff to facilitate discussion
about their collective involvement in research.
Residents
Care home staff approached residents whom they felt
had the mental capacity to consent to the qualitative
sub-study. Residents were considered eligible to partici-
pate in the qualitative sub-study even if they had not
given consent to participate in the PAAD stage 1 study.
14 residents consented to the study, all of whom had
consented to take part in PAAD stage 1. Interviews were
conducted in a private room within the care home
(usually the resident’s bedroom) by a research nurse
(HP). Interviews lasted between 9 and 54 minutes with
an average of 23 minutes. Each resident was offered £25
in recognition of their time.
Relatives
14 relatives of residents (4 partners and 10 sons or
daughters) were also invited by the care home staff to be
interviewed (all of whom had given advice as a personal
consultee that their relative should be part of PAAD
stage 1) and all consented. Interviews were conducted in
a private room within the care home by a research nurse
(HP). Interviews lasted between 12 and 31 minutes with
an average of 19 minutes. Each relative was offered £25
in recognition of their time.
Care home staff
Each care home was asked to nominate 3 members of
staff who were most closely involved with the PAAD
study. This staffs were invited to participate in a focus
group that took place at a city centre hotel. 19 staff
participated in the focus groups from 10 care homes.
Two focus groups were held, one with senior staff (10
participants) and the other with junior staff (9 partici-
pants), and each group discussion lasted approximately
90 minutes. The focus groups were facilitated by a re-
search nurse (HP) and a qualitative researcher (FW),
both of whom were experienced in running focus groups
but neither of whom had had prior contact with the care
home staff regarding the PAAD study. Since care home
staff were participating ‘off duty’, £25 was offered to each
participant. Lunch was provided, and travel expenses
were reimbursed.
General Practitioners (GPs)
Senior care home staff were asked to name the main GP
who attended patients within the care home. Letters of
invitation were sent to 11 GPs and two GPs responded.
In view of this, the researchers directly contacted sixty-
nine other GPs in the Health Board area to request an
interview, which resulted in 10 GPs agreeing to take part
in face-to-face interviews. (Three of these GPs were
aligned to a care home participating in PAAD Stage 1,
while seven were not, although nevertheless attended
people in care homes). GP interviews lasted between
20 minutes and 35 minutes with an average of 27 mi-
nutes. GPs were offered £50 for their time.
Data collection
An interview topic guide defined the main topics whilst
allowing flexibility to pursue issues in more depth as they
emerged from the interviews and focus groups (see
Additional files 1,2,3 and 4). Broad subject areas included
their views of the consent processes that had been used
for PAAD stage one and their experiences of participating
in PAAD stage one, where appropriate. We collected data
on the various merits and problems associated with a
number of models of consent that could be used for a trial
that lasts a reasonably long period such as 12 months (see
Additional file 5). Discussion also covered how consent
discussions should take place (for example, with a witness,
over the phone, in person, by post). Respondents were
asked what time frame they felt advanced consent should
cover. In addition, the researcher presented the respond-
ent with a range of hypothetical scenarios about taking
advanced consent and asked the respondents to reflect on
the potential advantages and disadvantages. They were
also asked for their opinion on what should happen
should the resident lose (and potentially regain) capacity
during a research trial. Data from the focus groups and in-
terviews were audio-recorded and transcribed verbatim.
Data analysis
Data were analysed using thematic analysis with an
abductive approach (incorporating themes that had been
identified in advance and themes that were derived from
the data) [27]. This approach involves systematically
coding data according to a thematic framework, which is
developed iteratively. Researchers met regularly to com-
pare coding, discussing evidence for themes, and came
to a consensus on the final framework. The thematic
framework was applied to the data using the coding soft-
ware package NVivo 8 [28]. Interpretations were discussed
between all authors.
Ethical approval
South East Wales Research Ethics Committee approved
the study (10/WSE03/31). All potential respondents were
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provided with an information sheet and all respondents
gave written informed consent prior to data collection.
Results
Four main ethical topics emerged from the data. These
were: 1) respondents’ assessments of harms and benefits
of participating in the observational study and the pro-
posed trial; 2) the process of gaining informed consent;
3) views about models of advanced consent; and 4) what
should happen when residents lose capacity during a
trial. Data extracts, including the respondent identifica-
tion number, are used to illustrate the themes.
Respondents’ assessments of the harms and benefits of
participation in research studies
Respondents generally had few concerns about low-risk
observational studies. Residents reported that they
wanted to participate in the PAAD study as it was an
interesting topic, and they wanted to participate altruis-
tically on the basis of helping science and reducing
diarrhoea in their care home. A few residents who had
consented to the PAAD stage 1 study subsequently with-
drew, and care home staff suggested that these residents
might not have fully understood the study when consent
was given. “I think that’s why they’ve withdrawn, because
they didn’t fully understand at the beginning, or, they may
have forgotten, just because of, you know, slight memory
problems”. (Focus Group, senior staff ).
Similarly relatives felt that the PAAD study was “rela-
tively harmless” and could see the potential benefits to
medicine and society “well, any advance in science is
worthwhile” (Interview, Relative 2), as well as the poten-
tial benefits to their family member in the care home
“it’s for her benefit at the end, the long term isn’t it?”
(Interview, Relative 8). However, a few relatives did have
some general concerns, for example whether the pro-
posed intervention had been tested on healthy popula-
tions. While most relatives expressed full support for
research conducted in care homes, a few stated they had
concerns that residents were too elderly or frail and their
participation in research was inappropriate (despite the
residents sometimes themselves being mentally capable
and having consented to take part).
Care home staff reported that one of their main rea-
sons for participating in research generally was that
older people, and care homes settings more specifically,
had traditionally been neglected in medical research “be-
cause there isn’t a lot of research in elderly care, we just
felt that it’d be nice to do something that would be re-
search based” (Focus Group, junior staff ). They also felt
that there were professional benefits of being involved in
university based research, supported by training, that
would motivate the staff “you need something to bring
you up, bring you out, make sure that you’re still doing
something with your career, if you like, and we did, we
sat down at one of our meetings, for the qualified and we
talked about it, and felt it would be good for us, stimu-
late us.” (Focus Group, senior staff ). Care home staff
also felt that the PAAD study topic (antibiotics and diar-
rhoea) was an important issue for them. “I think from
our point of view, we see lots of antibiotics prescribed
regularly, and all too often, not perhaps the correct anti-
biotic being prescribed, which does have the effect of diar-
rhoea” (Focus group, senior staff ).
Some GPs were concerned about how they, or their
GP colleagues, would be financially reimbursed for their
role in the PAAD Stage 2 study, but others reflected that
the PAAD study would be clinically useful and would
benefit GPs educationally, perhaps through increased
awareness of antibiotic associated diarrhoea within care
homes. “Rates of C.diff or harm that comes from it […]I
think you have to see it as something clinically useful, as
something that is going to make a clinical difference in
the end’ (Interview, GP 8).
The process of obtaining consent
Residents were generally supportive that relatives should
be asked to act in the capacity of a personal consultee or
a personal legal representative. Most felt that the relative
would have a good idea of their wishes and that it would
be better to ask a relative than a professional legal repre-
sentative as the former would know the resident well.
“Oh yes, a relative, yes, because I think they know you
better, and you understand them better” (Interview, Resi-
dent 10). However, one resident doubted whether all rel-
atives could be trusted to act in the best interests of
residents “you don’t know see, whether they’re [the fam-
ily] all that trustworthy” (Interview, Resident 9). Other
residents felt that some relatives may not want to be
bothered and may be too busy to help. Other potential
problems included difficulties with relatives who live a
long way from the care home, and some relatives them-
selves being mentally incapable.
Many relatives reported that they had wanted more
details about the PAAD study in the information sheet
(4 pages long), while others reported that they were
overwhelmed with the paperwork, and wanted the infor-
mation in a simple and short format. The relatives in-
cluded in the sample for the qualitative sub-study were
typically regular visitors at the homes. Many reported
that they found their close relationship with the resident
and with care home helpful when being asked to be a
personal consultee. They felt they knew the residents’
wishes well: “I think they [residents] trust their relative
to act on their behalf. I think a stranger coming in and
trying to talk them into doing something, they would be
on their guard” (Interview, Relative 12). It was felt that
relatives who visit irregularly, or who have little contact
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with the home, would feel more anxious about being
asked to take on the role of personal consultee or per-
sonal legal representative, partly because they would not
be able to personally monitor the resident’s condition
and partly because trust would be less well established
between care home staff and relatives “I would probably
say no [to acting as a personal legal representative] if I
was here only once a month to be honest with you”
(Interview, Relative 8).
Although the care home staff were motivated to par-
ticipate in PAAD, most staff were surprised at the scale
and intensity of the workload involved with implementing
research and with the time required for consenting pa-
tients “it’s also finding the time to do the consenting, and
spend that extra bit of time to talk through, ‘cos we’re
getting them interested in it, you know, um, well we did
find that a bit hard, just getting the time and really sit
down, ‘cos with 54 residents, and getting the relatives in,
a lot of them would come in after tea-time, which is a
really busy time, you know around tea-time, after tea-
time, a really busy time, only two qualified on, quite
hard then” (Focus group, senior staff ). Focus group par-
ticipants reported that senior staff were better able to
seek consent from relatives than junior staff. Specific diffi-
culties included: i) communicating with relatives who vis-
ited infrequently, ii) locating a nominated consultee when
no relative could be found, and iii) explaining the study to
residents considered to have capacity, only for the resident
to forget the purpose of the study afterwards. Some staff
reported that relatives wanted simple explanations and
were slightly put off by the length of the information
sheet: “I think the way it will be written down will make a
lot of difference as to whether people consent or not be-
cause, you know, a lot of words can sometimes put people
off, if it’s a lot of terminology” (Focus group, junior staff ).
Simplified information sheets, which had been designed
for residents, were consequently sometimes used with
relatives.
Some GPs reflected on the difficulties in obtaining
consent from older people with cognitive impairments.
They had concerns that residents would forget import-
ant details about the study, even during the time they
were given to reflect on their participation. In view of
this, some queried whether truly informed consent could
ever be obtained. The majority of GPs felt that most rel-
atives would be happy to be a personal consultee or a
personal legal representative and relatives would consent
to the PAAD study since it was a “benign study” (Inter-
view, GP 08). However one GP felt uncomfortable in-
cluding patients without capacity in a trial on the basis
of another’s advice “I don’t feel comfortable about it at
all because it, partly because I, I do feel that the patient
should be able to give informed consent if they are receiv-
ing something that is out of the ordinary from their usual
treatment” (Interview, GP 5). Another GP stated that
relatives may not always act in the resident’s best inter-
ests, “I’m not always convinced that relatives act in the
patient’s best interests” (Interview, GP 4). Moreover, a
few GPs felt that some relatives would not want to take
on this responsibility and some may also be unable to
retain or understand the information, “it’s possible that
the relative might be very elderly as well, and maybe los-
ing their memory too” (Interview, GP 2).
Views about models of advanced consent
All but two of the residents stated that they would be
happy to be consented just once to a 12 month study
and it was not necessary to keep checking throughout
the year to see if they still wanted to be involved “once
in the beginning, I think that would be sufficient” (Inter-
view, Resident 9). However, residents wanted to ensure
that they could withdraw during the study “I think um,
there should be um, an escape route if you like” (Inter-
view, Resident 12). Other respondents suggested that
their doctor should check every few months to ensure
that they were well enough to participate in the study. In
this respect, they wanted to be checked for eligibility ra-
ther than for consent.
None of the 14 relatives we interviewed expressed any
major concerns about obtaining advanced consent for a
study lasting 12 months. Generally they understood why
obtaining advanced consent was required, although two
relatives commented that 12 months can be an important
time span, with residents’ health deteriorating considerably
in this time. Relatives’ opinions on whether the research
team needed to re-consent during the 12 months were
divided. Three relatives felt that consent needed to be
checked at regular intervals (typically every 3–6 months),
although none of these relatives felt that this re-consent
needed to be established in writing. Four relatives felt that
it was not necessary to re-consent but that the care home
staff should continue to remind relatives informally that
the resident was still enrolled in the study “well, if you’ve
given consent, it might be nice to be reminded of it, you
know” (Interview, Relative 13). Seven relatives stated that
re-consenting during a 12-month study was not required,
as long as it was made clear that residents and relatives
had the right to withdraw from the study.
Care home staff did not see a problem with using a
model of advanced consent as they regularly used this
method to gain consent for activities such as taking pho-
tographs within the care home or taking residents on
outings. Care home staff thought that residents, or their
legal representatives, should be reminded of their par-
ticipation at the point of randomisation.
The majority of GPs felt that re-consenting during the
course of the year would be unnecessary paperwork. One
GP also raised the issue of how this could be managed if
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trial participants were to lose capacity during the study
period “I suppose the issue would be for someone who went
from having capacity to losing capacity, and if you’re going
to do, re-consent, you’re going to have to re-consent every-
body, because it ought to be consistent.” (Interview, GP1)
However, some GPs did comment that it would be appro-
priate, and a matter of courtesy, to verbally remind resi-
dents (or relatives in cases where residents do not have
capacity) at 3–4 month intervals that they are still part of
the study, and are free to withdraw at any time.
What should happen if a resident loses mental capacity
during the trial?
Mental capacity relates to the ability of a person to make
a specific decision at a particular time. For the PAAD
study, senior care home staff were tasked with assessing
whether residents had capacity to give consent for them-
selves or whether a personal consultee would need to be
approached for their advice. PAAD stage 2 is planned as
a 12 month study. Consequently, residents may consent
in month 1, but could be randomised to either probiotic
or placebo at any time between month 1 and month 12
depending on when they are next prescribed an anti-
biotic. It is possible that, if they were assessed for mental
capacity at the point of randomisation, they would no
longer be deemed as having mental capacity for the deci-
sion of whether or not to participate in the PAAD study.
Residents were divided on whether they should continue
to participate in the study without further consent from
a relative if they lost mental capacity during the study.
Some felt that if they lost mental capacity during that
time they would want to continue regardless, “I would
say exceptionally, I would want to proceed with the sur-
vey [research study], because it’s so important” (Inter-
view, Resident 12). However, some felt that the resident
would need reassessment by a health professional, “I’d
want you to check with my doctor to make certain it
wasn’t doing any harm, because if my mental facility
was going, I might be, it might be caused through that
[the study drug]” (Interview, Resident 3). Opinions
were divided on whether to give this decision to the rela-
tive, “the people doing the, er, research, I think they
should really ask whoever is acting on their behalf”
(Interview, Resident 13), or the GP “I think it must de-
pend on the doctor, the GP who is in touch with the resi-
dent” (Interview, Resident 12).
Relatives also differed in their opinions of this issue.
Five relatives felt that a relative should be consulted
about the resident’s continued participation “you’re going
to want somebody to act on his behalf” (Interview, Rela-
tive 1), while four others felt that a relative should just
be informed, as a matter of courtesy, that the resident
had given their consent to participate in the study “you
know maybe it would just be like an act of common
courtesy” (Interview, Relative 14). However, five relatives
felt that the resident should continue in the study re-
gardless of whether a relative is informed or has given
their consent. Many of the relatives acknowledged that
this was a difficult issue. Some argued that relatives
might have very strong views about this, but none spec-
ulated what might happen should a relative disagree with
a resident’s continued participation.
With the exception of only a couple of individuals, all
members of staff felt that if a resident loses capacity dur-
ing a trial, then a legal representative would need to be
approached and consent taken. When it was explained
that, legally, this was not the case, some care home staff
still insisted that they would still want to do this to
“cover themselves”. At an absolute minimum, they felt
that they should inform the relatives. “Well, I think you’d
have to re-consent with somebody that could give, well I
feel I’d have to ask the next of kin, if we could carry on, I
really do feel I’d have to do that.” (Focus Group, senior
staff ).
With the exception of one GP, who said that he felt
relatives should be approached for consent should a resi-
dent lose capacity, all felt that a resident should be
allowed to continue in the trial. Most GPs said that it
would be appropriate to inform the next of kin that the
resident had consented in the study, but (with the excep-
tion of the one GP previously mentioned) no GP sug-
gested that the relative could over-ride the resident’s
wishes. The fact that residents could lose (and regain)
capacity during the study supported their arguments
that residents did not need to be re-consented during a
trial lasting 12 months, as it would be impossible to re-
consent those who had originally given consent for
themselves and then lost capacity. They argued that if
residents were to re-consent, we would need to do this
consistently across the study population regardless of
whether or not they had lost (or gained) capacity.
Discussion
This qualitative sub-study about consent and recruit-
ment of care home residents to research found that resi-
dents, relatives, care home staff and GPs are generally
supportive of older adults in care homes participating in
research studies. However, respondents were concerned
about the best way of facilitating this, and some subtle,
but important differences of opinion in how older adults
should be recruited into studies were apparent.
One important issue relates to the comprehension and
retention of study information to achieve an optimal
level of informed consent. Residents and relatives were
generally accepting of studies which they believed to be
low risk and answered important questions that were in
the interests of care home residents and the care home.
However, some residents and relatives struggled to make
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sense of the purpose of the research and what was being
asked of them. Previous research has shown that an accur-
ate and comprehensive Participant Information Sheet
(PIS) is not enough to ensure comprehension of the main
issues [29]. In our study this was evidenced by some resi-
dents withdrawing from the study after initial consent,
and relatives struggling with long detailed information
sheets which sometimes care home staff supplemented, or
substituted, with the short, graphically illustrated, infor-
mation sheet which had been designed for residents. The
data from our qualitative sub-study therefore confirm the
importance of researchers and ethics committees making
every effort to improve the quality of consent discussions
and consent documents, ensuring use of familiar words
and ideas, short sentences and paragraphs and routinely
computing the reading ease of information sheets [30].
The comprehension and retention of information by
residents and their relatives becomes even more of a
challenge in a study which lasts a reasonably long period
of time (12 months in our case), and when some rela-
tives, asked to act in the capacity of a personal consultee
or a personal legal representative, are themselves frail
and at risk of becoming cognitively impaired. However,
these specific challenges, and challenges raised by other
researchers, are not a reason to exclude older adults
from research. While it is important not to underesti-
mate the difficulties, recruitment strategies need to be
developed in order to maximise the involvement of frail
older people while at the same time protecting their
right to decline participation. While PISs are highly
standardised, those who recruit older adults to research
studies will need training in methods of communication
which promote collaborative decision making and enable
them to convey complex principles such as equipoise
and randomisation in appropriate language. Recruitment
of older people, both with and without capacity, to re-
search studies can be complex but the awareness and
integrity of the researcher is fundamental to maintaining
the principle of non-exploitation [5]. Particular attention
should be given to assessing visual and auditory and
mental status, compensating for communication and
sensory deficits through the use of innovative consent
procedures such as pictorial information sheets and
interactive tools that help researchers to assess the po-
tential participants’ understanding and retention of in-
formation relevant to the study [8]. The second main
issue relates to the role of personal consultee, or per-
sonal legal representative, particularly when a research
subject loses mental capacity during a research study or
trial. Some relatives expressed the view that the person
they were related to was too elderly or frail and their
participation in research was inappropriate, despite the
resident themselves having had capacity to decide that
they wanted to take part. If these relatives were to act as
a personal consultee or legal representative it is uncer-
tain whether their advice or decision on inclusion would
reliably reflect the resident’s wish rather than their own.
This was indeed raised as a concern by one resident. It
is noteworthy also that one of the 10 GPs interviewed
did not agree with including adults without capacity into
any trial of a medicinal product. It is perhaps worth ex-
ploring the extent of this attitude amongst a larger and
broader sample of GPs, health professionals, and care
home staff, as if this belief is widely held it is likely that it
will be a barrier to improving recruitment of this under-
represented group into research trials, despite their heavy
use of a wide range of health care technologies.
In a study that lasts 12 months, it is likely that some
care home residents who originally have capacity to give
consent, may lose mental capacity. Furthermore it is not
unusual in such an age group for capacity to be tempor-
arily lost, for example due to delirium associated with a
urinary tract or chest infection [31]. One important find-
ing of our study was that many staff, relatives and resi-
dents felt that if a resident loses capacity during a clinical
trial, then a legal representative must be consulted about
their continued participation in the study. This is in con-
trast to the majority of GPs who believed that this would
not need to be the case. The Mental Capacity Act makes
provisions for a personal consultee to advise on the con-
tinued participation of the research subject in studies, [32]
but this is in contrast to clinical trials of medicinal prod-
ucts, where consent from an adult to participate in the
trial remains valid, even after loss of capacity, provided the
trial is not significantly altered.
Limitations of the study
While this qualitative sub-study incorporates views from
a wide range of stakeholders, we acknowledge that our
data may be biased. For example, we were only able to
interview relatives who were regular visitors to the care
homes, residents who had capacity, and care home staff
who were interested in participating in research. Although
residents and relatives who had declined their consent to
participate in PAAD stage 1 were invited to participate in
the sub-study, only those residents and relatives who had
agreed to participate in the main PAAD stage 1 study
agreed to participate in the sub-study. This could have
resulted in a biased sample that included more people
who were more accepting of research. We also do not
know how many residents were approached by care home
staff to participate and declined to be interviewed, which
may be a source of potential bias.
Furthermore the GPs who agreed to be interviewed
may have been more knowledgeable of research ethics.
We also acknowledge that our respondents may not
have been so supportive of research had the trial within
which we embedded our research been perceived as
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more harmful. In our analysis we have tried to reflect
general issues about the ethics and practical issues of
conducting trials in care home settings, rather than
focus on the specifics of the PAAD study. This qualita-
tive sub-study was undertaken in care homes in South
Wales, and further work could be undertaken to further
explore whether these issues remain relevant in other
settings and amongst other populations.
Conclusion and recommendations
Although care home environments pose practical prob-
lems to researchers, our findings should inform other
research teams that care home residents, relatives and
staff may be generally very supportive of participating in
research. Given that older people are the heaviest con-
sumers of health and social care, challenging ageist prac-
tices and attitudes in research is important if they are to
gain maximum benefit from advances in understanding
and management. Ethics committees are also in a strong
position to influence research practice and to reduce un-
ethical discrimination on the grounds of age or social
situation, by challenging researchers who continue to ex-
clude these groups from research.
Research teams should consider using models of ad-
vanced consent for trials of interventions where there is
a high likelihood that participants may not have capacity
at the point of randomisation. We would also recom-
mend that researchers who are conducting trials of me-
dicinal products in care home settings ensure that care
home staff and residents are made aware that residents
who have consented themselves to a study have the legal
right to remain in the trial if they lose capacity during
the study period, provided the person has not indicated
a different choice.
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